Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance

N/AUnknownNCT01191099

University of Zurich150 enrolled

Overview

A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer

1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers 2. To characterize expression and hypoxia/HIF-responsiveness of myoglobin, cytoglobin, α-hemoglobin in prostate tumors and cell lines 3. To identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancers

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Prostate Cancer

Interventions

PimonidazolDEVICE

0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion criteria: * Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich * Written informed consent Exclusion criteria: * Metastatic prostate cancer * Contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product * Severe heart or lung disease * Severe liver or kidney dysfunction * Severe stridor * Distant metastases * Concurrent treatment for other malignant disease * Prior hormonal therapy or radiotherapy

Locations (1)

University Hospital Zürich

Zurich, Switzerland

RECRUITING

Central Contacts

01 Studienregister MasterAdmins

CONTACT

+41 (0)44 255 11 11

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.